Chamber and committees

Toxics use reduction as a concept is already well embedded in the regulatory system on chemicals safety in Great Britain. This system includes UK REACH (Registration, Evaluation, Authorisation and restriction of Chemicals) regulation, part of the post-brexit chemicals regulatory framework we inherited from the EU. It includes specific provisions to prevent the use of harmful substances, ensure mitigations are in place to reduce exposure from such chemicals where their use is essential, and reduce risks associated with chemical use more generally.

The Scottish Government regularly monitors for hazardous substances in the Scottish marine environment. Hazardous substances highlighted to be of particular concern and routinely monitored include heavy metals (cadmium, mercury and lead), polychlorinated biphenyls (PCBs), polybrominated diphenyl ethers (PBDEs) and polycyclic aromatic hydrocarbons (PAHs). These contaminants are measured in biota (mussels and fish) collected as part of the UK Clean Seas Environment Monitoring Programme for four biogeographic regions: Irish Sea (Clyde and Solway), Minches and Western Scotland, Scottish Continental Shelf and Northern North Sea.

More information related to the testing for contaminants in marine animals in Scottish waters can be found in the Scotland's Marine Assessment 2020 | Scotland's Marine Assessment 2020 .

As this is an operational matter for Scottish Water, and the Scottish Government does not hold this information, I have asked them to respond. Their reply is as follows:

Scottish Water is currently developing its Long Term Strategy, due for publication in January 2025, which will include the investment requirements for addressing the forecast supply-demand deficits through demand reduction activities, increased connectivity between supply systems and potentially new water sources.

Scottish Water is also working on a zonal model which will inform the strategic choices for managing their supply-demand balance. Scottish Water is in the middle of the detailed planning activities and will be in a position to respond to the specifics of this query by the end of December 2024/early in 2025.

The Scottish Government is aware that supplies of various ADHD medicines continue to be intermittent. At present, market data and information provided by the UK Government indicates that some of these supply issues will continue into Autumn 2024. Scottish Government officials continue to monitor the situation for any further developments and are maintaining a close dialogue with all Health Boards to help manage these medicine supply disruptions and provide support when needed.

The supply of medicines and associated legislation are a reserved matter for the UK Government, and we continue to engage with them on this supply issue and other medicine shortages. The Chief Pharmaceutical Officer for Scotland is a member of a UK-wide Medicines Shortage Response Group, set up to identify and co-ordinate responses to medicines shortages across the UK and provide advice to prescribers on alternative therapeutic options.

The UK Government’s Department of Health and Social Care, on behalf of all four nations, regularly meets with the manufacturers of ADHD medicines to discuss their supply chains challenges and any issues where they may require assistance, including providing an overview of current and forecasted demand to assist manufacturers with planning to increase production forecasts. T he Scottish Government has not had any separate engagement with the manufacturers of ADHD medicines.

While the Scottish Government are responsible for the strategic direction of the NHS, territorial Health Boards and Integration Authorities are responsible for delivering services in their areas, including the amount spent on each of the service areas delivered by the Primary Care Improvement Fund (PCIF). Integrated Authorities must work closely with local communities and other stakeholders to ensure that Primary Care Improvement Plans address specific local challenges and population needs while taking into account the guidance in the GP contract and accompanying MoUs as well as amended regulations.

The Marine Fund Scotland (MFS) has paid £11.63m to applicants who were awarded total funding of £14m in 2023-24. Individual awards are published here - https://www.gov.scot/publications/marine-fund-scotland-grants-awarded/ . The Scottish Government publishes all payments over £25k here - https://www.gov.scot/collections/government-spend-over-gbp25000-monthly-reports/ .

The remaining £2.37m funding supported data collection on stocks in the North Sea and the West of Scotland. This information is combined with data from other European nations who fish in these waters and is then considered by the International Council for Exploration of the Seas (ICES).

The Scottish Government is aware that there are global supply issues with Pancreatic Enzyme Replacement Therapy (PERT) medicines, including Creon ® , which are licensed for the treatment of pancreatic exocrine insufficiency for those with cystic fibrosis.

While the supply of medicines and the associated legislation are a reserved matter for the UK Government, Scottish Government officials continue to engage with them on this supply issue and other medicine shortages. The Chief Pharmaceutical Officer (CPO) for Scotland is a member of a UK-wide Medicines Shortage Response Group (MSRG), set up to identify and co-ordinate responses to medicines shortages across the UK and provide advice to prescribers on alternative therapeutic options.

In May, the Scottish Government issued a Medicine Supply Alert Notice (MSAN) and National Patient Safety Alert (NatPSA) which outline actions to be taken by prescribers to ensure patients are moved onto alternative treatments and measures to help conserve stocks of PERT medicines, including Creon ® .

The Good Food Nation (Scotland) Act 2022 requires relevant authorities to publish a Good Food Nation Plan within 12 months of the date that Section 10 of the Act comes into force. It is the Scottish Government’s intention to commence this part of the legislation at around the same time as the final version of the national Good Food Nation Plan is published in 2025. Relevant authorities will therefore be required to publish their own Plans in 2026.

The Scottish Government’s recent investment into diabetes technologies will specifically support children and adults to access closed loop systems.

Alongside this additional investment, we will also encourage all NHS Boards including NHS Lothian to utilise the national onboarding team based at Centre of Sustainable Delivery as well their own local diabetes clinical teams to support technology starts.

This should increase the rate and scope at which individuals will be able to access closed loop systems and therefore have a positive impact on waiting times.

The Young Person’s Guarantee was introduced in response to the Covid-19 pandemic as a measure to prevent long-term adverse impacts for young people in the labour market. It contained a number of aspects, covering skills, education, and employability.

Employability support available through the Young Person’s Guarantee was delivered through Local Employability Partnerships, with Local Authorities acting as lead accountable body. Specific details on funding are not held by the Scottish Government, therefore requests for this information would need to be directed towards Local Authorities. Employability contacts for each local authority can be found on the Employability in Scotland website which can be accessed here: https://www.employabilityinscotland.com/local-employability-services/

Employability support for young people is now delivered through the No One Left Behind approach across Scotland including Edinburgh, as part of the long-term ambition to simplify the employability landscape for service users.